Outcomes and risk factors of SARS‐CoV ‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy
Cancer Medicine · 2023
DOI: 10.1002/cam4.6657 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Xibin Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, COVID-19, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Medical Health Science and Technology Project.
Abstract (Originalsprache)
Background
Little was known on infection and mortality rates, still less the risk factors of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) omicron variant in B‐cell lymphoma patients following CD19 targeted chimeric antigen receptor T cell (CAR‐T).
Aims
We performed a retrospective multicenter study and analyzed the details of relapsed/refractory (R/R) B‐cell lymphoma patients who received CD19 targeted CAR‐T heretofore in five cellular immunotherapy centers in China during the omicron wave. Materials & Methods One hundred fifty‐four patients were enrolled in this study.
Results
Among them, 52 patients (33.8%) were uninfected, 74 patients (48.1) had ambulatory mild disease (including nine patients of asymptomatic infection), 22 patients (14.3%) had moderate disease and six patients (3.9%) had severe disease when data collected up. Three patients with severe disease died from COVID‐19, the death rate was 1.9% for all enrolled patients, and 2.9% for infected patients. We also found that patients over 60 years old or with diabetes mellitus (DM) tend to develop severe disease ( p = 0.0057 and p = 0.0497, respectively). Patients had CAR‐T infusion within 6 months also tend to have severe disease ( p = 0.0011). In multivariate logistic regression model, CAR‐T infusion within 6 months (relative risk (RR) 40.92; confidence interval (CI) 4.03–415.89; p = 0.002) were associated with significantly higher risk of severe disease.
Conclusion
Through this study, we conclude that the outcome for B‐cell lymphoma patients following CD19 targeted CAR‐T therapy when facing omicron infection was improved, but aggressive precautionary measures were particularly crucial for patients with high risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Bio-Therapeutic, The First Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.
- Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Hematology Oncology, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Hematology, Yinzhou Hospital, Affiliated to College of Medicine, Ningbo University, Ningbo, China.
ORCID-Profile: Hui Liu
Förderung
- Zhejiang Medical Health Science and Technology Project
Zitieren
APA
Xiao, X., Chen, P., Zhong, Y., Luo, X., Liu, Y., Lu, Y., Jin, X., Qian, W., Han, W., Liang, A., & Liu, H. (2023). Outcomes and risk factors of SARS‐CoV ‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy. Cancer Medicine. https://doi.org/10.1002/cam4.6657
Vancouver
Xiao X, Chen P, Zhong Y, Luo X, Liu Y, Lu Y, et al. Outcomes and risk factors of SARS‐CoV ‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy. Cancer Medicine. 2023. doi:10.1002/cam4.6657
BibTeX
@article{Xiao2023,
author = {Xiao, Xibin and Chen, Panpan and Zhong, Yadi and Luo, Xiu and Liu, Yao and Lu, Ying and Jin, Xueli and Qian, Wenbin and Han, Weidong and Liang, Aibin and Liu, Hui},
title = {Outcomes and risk factors of SARS‐CoV ‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6657}
}
EUVIMED